Filter posts

The Bio Report: What a Decade of Investment Tells Us About the Health of Biotech

In this podcast, The Bio Report’s Daniel Levine interviews BIO’s Dave Thomas on the recent …

Riding the Bull Market: What’s in Store for Biotech Dealmakers in 2015?

In many ways, 2014 was a record year for biopharma dealmaking, with $355 billion in …

Complexities of Rare Diseases Take the Spotlight at BIO

Global Genes Founder & CEO Nicole Boice opened the BIO 2015 Orphan & Rare Disease …

Legislative Best Practices in Support of Bioscience Economic Development

Despite a difficult economic environment the past couple years, states across the country have found …

Business Development and Building the Relationship After BIO

There is a great energy here at BIO, and you can feel it as you …

Pharma R&D Pipeline Value Jumps 18 Percent to $493 Billion

The pharmaceutical industry continues its impressive two-year growth with no signs of slowing down according …

BIO Innovation Zone Company Snapshots: Iron Horse Diagnostics and Nimbic Systems

This week in Philadelphia at the BIO International Convention, BIO is partnering with the National Institutes of …

BIO Innovation Zone Company Snapshots: Aciont Inc. and TF Health Co.

This week in Philadelphia at the BIO International Convention, BIO is partnering with the National Institutes of …

BIO Is Almost Here – What To Consider Before Entering New Therapeutic Areas

Over the past decade, the biopharmaceutical industry has witnessed a shift towards specialty care. From …

BIO Innovation Zone Company Snapshots: AreteX Engineering

This month in Philadelphia at the BIO International Convention, BIO will be partnering with the National …